NOTCH1 signaling promotes protein stability of HER3 through the AKT pathway in squamous cell carcinoma of head and neck

• Published in: Oncogenesis (New York, NY) NY), 2021-08, Vol.10 (8), p.59-59, Article 59
• Main Authors: Wang, Yi-Ping, Liu, I-Ju, Chen, Kai-Chi, Wu, Han-Chung
• Format: Article
• Language: English
• Subjects: 38/79; 631/67/1536; 631/80/86; 64/60; 82/29; 82/51; 96/95; AKT protein; Animal models; Apoptosis; Cell Biology; Cell differentiation; Clinical trials; Epidermal growth factor; Epidermal growth factor receptors; Head & neck cancer; Head and neck carcinoma; Human Genetics; Immunoprecipitation; Internal Medicine; Kinases; Medicine; Medicine & Public Health; Metastases; Notch1 protein; Oncology; PD-1 protein; PD-L1 protein; Phosphorylation; Polymerase chain reaction; Post-translation; Squamous cell carcinoma; Transcription activation; Tumor cells; Western blotting
• ISSN: 2157-9024; 2157-9024
• DOI: 10.1038/s41389-021-00348-5

Epidermal growth factor receptor (EGFR) remains the sole druggable molecular target other than the PD1/PD-L1 pathway with meaningful clinical benefit in squamous cell carcinoma of head and neck (SCCHN). Human epidermal growth factor receptor 3 (HER3) confers the resistance to EGFR-targeted treatment in SCCHN. Thus, it is essential to determine the distribution and regulatory mechanisms of HER3 in SCCHN. We explored the prevalence of HER3 expression and its distribution within SCCHN by immunohistochemical staining and clinicopathological correlations were analyzed. The regulatory mechanism of HER3 expression was then dissected in vitro, using RT-PCR, Western blotting, and immunoprecipitation in a set of SCCHN cell lines. Subsequent in vivo validation in the murine model was also performed. We found that concomitant high expression of HER3 and its ligand NRG1 in SCCHN is associated with the increased presence of regional lymphatic metastasis and the majority of HER3 is located on the differentiated tumor cells. Further investigation revealed that HER3 is under positive control of NOTCH1 through transcriptional activation and inhibition of protein degradation through the polyubiquitination machinery via AKT pathway and USP8 deubiquitinating enzyme. In addition, loss of function of NOTCH1 suppresses HER3 expression through increased phosphorylation of serine 473 of AKT in SCCHN cells, and promotes the aggressiveness of the tumor cells. These data indicated that the level of HER3 is regulated by NOTCH1 in SCCHN both transcriptionally and post-translationally, and NOTCH1 is in a higher hierarchy in the regulatory system of the AKT pathway. Since NOTCH1 is inactivated in approximately 10% of SCCHN cases and this aberration strongly impacts the AKT pathway and diminishes HER3, exclusion of patients with NOTCH1-inactivated SCCHN may be beneficial for future clinical trials of HER3-targeting antibodies.